LCM
ZYNE

Landscape Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Landscape Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-35,860
Closed -$300K – 792
2017
Q3 		$300K Buy
+35,860
New +$379K 0.03% 397

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Landscape Capital Management's ZYNE Position: Q4 2017 in Review

Landscape Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2017, closing a stake of 35,860 shares — an estimated $300K sold.

Landscape Capital Management first reported a position in ZYNE in Q3 2017 and held it in 1 quarter. The position peaked at $300K in Q3 2017. 64 funds tracked by Wall St. Rank hold ZYNE as of Q4 2017.

  • Landscape Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Landscape Capital Management sold 35,860 Zynerba Pharmaceuticals, Inc shares in Q4 2017, an estimated $300K.
  • Landscape Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 1 quarter.
  • Landscape Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $300K in Q3 2017.
  • 64 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2017.

Based on Landscape Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.